Status:
COMPLETED
A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
Lead Sponsor:
Sihuan Pharmaceutical Holdings Group Ltd.
Conditions:
Duodenal Ulcer，DU
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A phase 2,double-blinded, double dummy, parallel, positive drug, randomised controlled multicenter trial to evaluate efficacy and safety of 4 weeks treatment of Anaprazole 20mg QD, 40mg QD compared wi...
Eligibility Criteria
Inclusion
- Age ≥18 years, male and female
- Has endoscopic diagnosis of active duodenal ulcer(s) (A1 or A2 stage) within 7 days prior to randomization
- 1 or 2 ulcers, 3-15 mm in diameter.
- Signed informed concent form
Exclusion
- Has malignancy ulcer or malignancy ulcer not excluded, compouned ulcer, stress ulcer, esophageal erosion and ulcer, reflux esophagitis, Zollinger-Ellison syndrome.
- Has esophageal and gastric varices；
- With severe compliaction, such as pyloric obstruction, bleeding (Forrest I, IIa and IIb) or perforation, and etc；
- Has other gastrointestinal disease (e.g.gastric ulcer), or has history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)；
- Has undergone surgical resection or partly resection of esophageal, stomach or duodenum；
- Has used Proton Pump Inhibitors(PPIs) within 5 days prior to randomization, or continuous more than 3 days of use of Proton Pump Inhibitors within 2 weeks prior to randomization；
- Has been treated with triple or quandruple Helicobacter pylori eradication therapy included PPIs within 28 days prior to randomization；
- Current use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory drugs, or anticoagulation drugs) which may induce ulcer or ulceric bleeding or continuous more than 3 days of use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory drugs, or anticoagulation drugs) within 28 days prior to randomization；
- Laboratory tests performed in screning stage revealed Alanine aminotransferase (ALT) or aspartate aminotransferase (AST): \> 1.5 upper limit of normal (ULN);
- Laboratory tests performed in screning stage revealed thyroid stimulating hormone (TSH)；
- Woman in pregnancy or lactation period；
- Plan for pregancy or not willing to contracept with reliable contraception method during study period and within 90 days after the final time of investigational drug administratio；
- Have alcohol abuse or drug abuse 1 years prior to screening；
- Has hypersensitivity or allergy to investigatory drug, comparatory drug or related supplements；
- Has participated or been participating other clinical trials(non-interventional study is excluded)；
- Has an uncotroled disease, such as has a history of significant central nervous system (CNS), cardiovascular, pulmonary, hepatic, renal, or mental or psychological disorders with drug treatment that,in the opinion of the investigator, would not be suitable for participating this clinical trial.
- In the opinion of the investigator, the patients with other situation would not be suitable for participating this clinical trial.
Key Trial Info
Start Date :
October 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 17 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04503629
Start Date
October 9 2018
End Date
May 17 2019
Last Update
August 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Fisrst Affiliated Hospital of NanChang University
Nanchang, Jiangxi, China, 330006